"A PHASE 1/2A STUDY OF BMS-986253 IN COMBINATION WITH NIVOLUMAB IN ADVANCED CANCERS."
- Registry ID
- CA027-002
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Start date
- 2022-06-15
- Last update
- 2018-07-13
Conditions
Related clinical trials
- A PHASE 1, FIRST IN HUMAN STUDY OF TORL-4-500
IN PATIENTS WITH ADVANCED CANCER
- PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
- PSILOCYBIN-ASSISTED EXISTENTIAL, ATTACHMENT AND RELATIONAL (PEARL) THERAPY FOR PATIENTS WITH ADVANCED CANCER: A PHASE II OPEN-LABEL TRIAL
- A PHASE 1, OPEN-LABEL, DOSE FINDING STUDY OF CC-95251, A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRP¿, ALONE AND IN COMBINATION WITH CETUXIMAB IN SUBJECTS WITH ADVANCED SOLID CANCERS
- A PHASE II STUDY OF DURVALUMAB AND TREMELIMUMAB IN PATIENTS WITH ADVANCED RARE TUMOURS
- AN OPEN LABEL, DOSE ESCALATION, SAFETY, AND PHARMACOKINETIC STUDY OF CFI-402257 ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER
View on source registry